

Antineoplastic Therapy and Immunotherapy Course Interventional Radiology Nurses

UPMC Hillman Cancer Center: Virtual via MS Teams

Day One: Wednesday, October 9, 2024

Day Two: Wednesday, October 16, 2024

Day Three: Wednesday, October 23, 2024

Day Four: Wednesday, October 30, 2024

Test Date: Thursday, November 14, 2024

Learning Objectives

After participation in this activity, the learner will be able to:

- Recall the side effect profiles for the different classes of antineoplastic agents.
- Recall nursing care considerations for patients receiving antineoplastic therapy.
- Apply principles of antineoplastic therapy drug administration in calculating drug doses to include calculation of body surface area (BSA), absolute neutrophil count (ANC), creatinine clearance (Cr Cl) and carboplatin dosing.
- Describe the steps to ensure safe administration of antineoplastic agents.
- Identify assessment priorities to effectively manage patient symptoms, dose-limiting toxicities, and adverse effects of antineoplastic therapy.
- Recognize relevant resources for proper use of personal protective equipment (PPE) and excretion precautions.
- Prioritize the appropriate interventions for the management of hypersensitivity reactions.
- Describe the appropriate interventions for the management of vesicant extravasation.
- Discuss the differences between cancer genetics and cancer genomics.
- Recall strategies to prevent medication errors.

Day One: Wednesday, October 9, 2024

7:30 am	Registration and Microsoft Teams Login	
8:00 am	Welcome and Course Overview	Maura Miller, DNP, APRN, FNP-BC, OCN
8:20 am	Principles of Antineoplastic Drug Therapy	Ernie Sanchez, PharmD
9:20 am	Antineoplastic Therapy Administration	Markie Rearick, MSN, RN, BMTCN
10:35 am	Break	
10:45 am	Extravasation	Nancy Birus, MSN, RN, OCN
11:15 am	Hypersensitivity	Alyssa Owens, MPAS, PA-C
11:50 am	Lunch	
12:30 pm	Error Prevention	Amy DiMaggio, MSN,RN, OCN
1:10 pm	Building Your Knowledge Case Studies	Lynne O'Connor, MSN, RN, OCN
2:00 pm	Break	
2:10 pm	Alkylating Agents	Maura Miller, DNP, APRN, FNP-BC, OCN
3:45 pm	Adjournment	Maura Miller, DNP, APRN, FNP-BC, OCN

Day 2: Wednesday, October 16, 2024

7:30 am	Registration and Microsoft Teams Login	
8:00 am	Welcome and Course Overview	Maura Miller, DNP, APRN, FNP- BC, OCN
8:05 am	Genetics vs. Genomics	Melissa K. Bourdius, MS, CGC
8:40 am	Antimetabolites	Tim George, PharmD, BCOP
9:40 am	Break	
9:50 am	Antitumor Antibiotics	Steve Moretti, PharmD
11:50 am	Lunch	
12:20 pm	Growth Factors	Emily Mueseler, MPAS, PA-C
12:50 pm	Understanding Organ Toxicity: Management and Adverse Events of Chemotherapy	Linda Pfeifer, CRNP, RN
4:00 pm	Adjournment	Maura Miller, DNP, APRN, FNP- BC, OCN

Day 3: Wednesday, October 23, 2024

Attendance is not required for IR Nurses on Day 3 Chemo Class

Day 4: Wednesday, October 30, 2024

7:30 am	Registration and Microsoft Teams Login	
8:00 am	Post Course Instructions	Maura Miller, DNP, APRN, FNP-BC, OCN
8:20 am	Plant Alkaloids	Marissa Lamary, PA-C
9:00 am	Homework Review	Lynne O'Connor, MSN, RN, OCN
9:45 am	Break	
9:55 am	Case Study	Maura Miller DNP, APRN, FNP-BC, OCN
11:45 am	Post Class Instructions	Maura Miller, DNP, APRN, FNP-BC, OCN
12:00 pm	End of Class/Adjournment	Maura Miller, DNP, APRN, FNP-BC, OCN

Course Exam

UPMC Employees, IR Nurse:

The IR nurse will receive an accreditation sheet once roster is verified for each class date and test is completed and passed with a score of 80% or greater. The test for the Antineoplastic Therapy and Immunotherapy Course for the IR Nurse will be assigned in HR Direct > Learning. The IR nurse will need to provide the following information to the course director <u>by Wednesday</u>, <u>October 23, 2024 (Day 3 of class) via email to Maura Miller kimballmk2@upmc.edu</u>

- Name of exam proctor and contact information
- Test date (if other than scheduled test date)

Fall Antineoplastic Therapy and Immunotherapy Course for the IR Nurse Test Date: Thursday November 14, 2024.

Nancy Birus, MSN, RN, OCN Clinical Education Specialist UPMC Hillman Cancer Center

Timothy George, PharmD, BCOP Clinical Pharmacy Specialist UPMC Hillman Cancer Center

Steven Moretti, PharmD Oncology Consultant Pharmacist Investigational Drug Service UPMC Hillman Cancer Center

Alyssa Owens, MPAS, PA-C Physician Assistant UPMC Hillman Cancer Center

UPMC Shadyside Hospital

Ernest M. Sanchez, Pharm.D. Lead Pharmacist of Oncology Operations, Department of Pharmacy

Faculty Listing

Melissa K. Bourdius, MS, CGC Genetics Counselor Special Genetic Counsel UPMC Magee-Womens Hospital

Marissa Lamary, PA-C Physician Assistant UPMC Hillman Cancer Center UPMC Shadyside

Emily Mueseler, MPAS, PA-C Physician Assistant UPMC Hillman Cancer Center

Linda Pfeifer, CRNP, RN Nurse Practitioner UPMC Hillman Cancer Center Amy DiMaggio, MSN, RN, OCN Clinical Education Specialist UPMC Hillman Cancer Center

Maura Miller DNP, APRN, FNP-BC, OCN Clinical Education Specialist UPMC Hillman Cancer Center

Lynne O'Connor, MSN, RN, OCN Advanced Clinical Education Specialist UPMC Hillman Cancer Center

Markie Rearick, MSN, RN, BMTCN Clinical Education Specialist UPMC Shadyside

Contact Hours

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The maximum number of hours awarded for this Continuing Nursing Education activity is 14.25 contact hours.

To receive 14.25 Contact Hours, the learner must sign into each class day via Microsoft Teams, attend all class days, and pass the exam with an 80% or greater. Following test completion, the learner will complete the evaluation on the CCE site and claim credit.

Disclosure of Conflicts of Interest

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following information was provided:

Nancy Birus, Melisssa K. Bourdius, Amy DiMaggio, Marissa Lamary, Maura Miller, Steven Moretti, Emily Mueseler, Lynne O'Connor, Alyssa Owens, Linda Pfeifer, Markie Rearick, Ernest Sanchez, and the planning committee for this activity did not have any relevant financial relationships with a commercial interest.

The following information was disclosed:

Timothy George: Stockholder: Syros Pharmaceuticals, Valneva